Coherus BioSciencesCHRS
Market Cap: $148M
About: Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Employees: 306
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
38% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 34
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
1% less funds holding
Funds holding: 135 [Q1] → 133 (-2) [Q2]
4.46% less ownership
Funds ownership: 75.71% [Q1] → 71.25% (-4.46%) [Q2]
30% less capital invested
Capital invested by funds: $202M [Q1] → $141M (-$60.4M) [Q2]
32% less call options, than puts
Call options by funds: $219K | Put options by funds: $321K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
UBS Ashwani Verma 47% 1-year accuracy 9 / 19 met price target | 16%upside $1.50 | Neutral Downgraded | 16 Aug 2024 |
HC Wainwright & Co. Douglas Tsao 60% 1-year accuracy 79 / 132 met price target | 830%upside $12 | Buy Reiterated | 5 Aug 2024 |
Baird Colleen Kusy 56% 1-year accuracy 9 / 16 met price target | 520%upside $8 | Outperform Maintained | 1 Jul 2024 |